Clearside Biomedical's Phase 2b trial for wet AMD treatment CLS-AX reported positive outcomes, outperforming aflibercept.

Clearside Biomedical's ODYSSEY Phase 2b trial for CLS-AX, an injectable treatment for wet age-related macular degeneration, reported positive outcomes, achieving both primary and secondary goals. CLS-AX maintained stable best corrected visual acuity and ocular anatomy for up to 6 months, outperforming aflibercept. The treatment showed a well-tolerated safety profile with no serious adverse events. Following the announcement, Clearside's stock rose over 25%.

October 09, 2024
5 Articles

Further Reading